How did liquid biopsy become one of the most important tools in modern oncology?

In Episode 7 of The Breast Friends Podcast, Dr. Jason Mouabbi and Dr. Paolo Tarantino are joined by Dr. Daniel Hayes, Past President of ASCO and one of the pioneers behind tumor markers and liquid biopsy in breast cancer.

From the mid-1980s breakthrough clinical discovery of CA 15-3 to the cutting-edge evolution of circulating tumor cells (CTCs), ctDNA, MRD, and multi-cancer early detection (MCED), Dr. Hayes shares the captivating behind-the-scenes stories, scientific milestones, and lessons that have shaped decades of breast cancer research.

This conversation is more than an oncology history lesson. It's a deep dive into the future of precision medicine, the reality of tumor heterogeneity, and the mystery of cancer dormancy that will define the next generation of cancer care.

🎙️ Hosted by Drs. Jason A. Mouabbi & Paolo Tarantino

▶️ Watch on YouTube - https://youtu.be/PvguD4bXN-E

🎧 Listen on Spotify, Apple Podcasts, iHeartRadio, CastBox, and Amazon Music - https://linkin.bio/breastfriendspodcast

📺 As Mentioned in the Episode:

Watch the historic interview featuring Dr. Daniel Hayes, Dr. Lawrence Einhorn, and John Cleland, the first patient ever cured of metastatic testicular cancer with platinum combination therapy: https://youtu.be/mKBQDSMInuI?si=YGvwlS-UfXlNvloP

The Breast Friends Podcast is part of the Community Health Media Podcast Network, where meaningful conversations help patients, caregivers, advocates, and healthcare professionals learn from one another, one story at a time.

#BreastCancer #Oncology #LiquidBiopsy #ctDNA #CTCs #PrecisionOncology #CancerResearch #MedicalOncology #ASCO #OncologyPodcast #MedEd

The HER2-positive revolution isn't coming. It's here.

In Episode 6 of The Breast Friends Podcast, Dr. Jason Mouabbi and Dr. Paolo Tarantino unpack the practice-changing data emerging from ESMO Breast 2026.

From DESTINY-Breast11 and DESTINY-Breast05 to the growing role of HER2DX, ctDNA, MRI-guided treatment adaptation, and chemotherapy-free strategies, this conversation explores a fundamental shift in breast oncology: moving from treating every patient the same to delivering truly personalized care.

Can we safely eliminate carboplatin?

Can biomarkers tell us who needs less treatment?

Is a chemotherapy-free future finally a reality for certain patients?

The future of HER2-positive breast cancer is being written right now.

🎙️ Hosted by Drs. Jason A. Mouabbi & Paolo Tarantino

▶️ Watch on YouTube - https://youtu.be/WrvmVGEgoIA

🎧 Listen on Spotify, Apple Podcasts, iHeartRadio, CastBox and Amazon Music

#BreastCancer #HER2Positive #Oncology #OncologyPodcast #ESMOBreast #CancerResearch #ClinicalTrials #PrecisionMedicine #MedicalOncology #MedEd #Enhertu #TDXd

What shaped modern breast oncology and what comes next?

From the pioneering HER2 breakthroughs to the recent innovation of ADCs and oral SERDs, Dr. Rugo provides a masterclass on the therapies that are changing the standard of care. The discussion also looks ahead, exploring the clinical utility of ctDNA monitoring and the critical importance of preserving quality of life in the metastatic setting.

From HER2 breakthroughs and ADC innovation to oral SERDs, ctDNA monitoring, quality of life, and the future of metastatic breast cancer care, this conversation is a masterclass in where the field has been and where it’s heading next.

This is oncology history, innovation, and the future all in one conversation.

🎙️ Hosted by Drs. Jason A. Mouabbi & Paolo Tarantino

👤 Featuring Dr. Hope Rugo

▶️ Watch on YouTube - https://youtu.be/IGbXzLpE-LY

🎧 Listen on Spotify, Apple Podcasts, iHeartRadio, CastBox and Amazon Music

#BreastCancer #Oncology #OncologyPodcast #HopeRugo #CancerResearch #ClinicalTrials #PrecisionMedicine #MedicalOncology #MedEd #ADC